Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Other Non-Current Assets (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Other Non-Current Assets data on record, last reported at $837000.0 in Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 90.72% year-over-year to $837000.0; the TTM value through Sep 2025 reached $837000.0, down 90.72%, while the annual FY2023 figure was $7.3 million, N/A changed from the prior year.
  • Other Non-Current Assets reached $837000.0 in Q3 2025 per ZBIO's latest filing, up from $209000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $9.0 million in Q3 2024 and bottomed at $86000.0 in Q3 2023.
  • Average Other Non-Current Assets over 3 years is $3.5 million, with a median of $837000.0 recorded in 2025.
  • Peak YoY movement for Other Non-Current Assets: surged 10388.37% in 2024, then crashed 90.72% in 2025.
  • A 3-year view of Other Non-Current Assets shows it stood at $7.3 million in 2023, then rose by 23.97% to $9.0 million in 2024, then plummeted by 90.72% to $837000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $837000.0 in Q3 2025, $209000.0 in Q1 2025, and $9.0 million in Q3 2024.